JP2005525414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525414A5 JP2005525414A5 JP2004502918A JP2004502918A JP2005525414A5 JP 2005525414 A5 JP2005525414 A5 JP 2005525414A5 JP 2004502918 A JP2004502918 A JP 2004502918A JP 2004502918 A JP2004502918 A JP 2004502918A JP 2005525414 A5 JP2005525414 A5 JP 2005525414A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- antigen
- lna
- formulation
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 238000000034 method Methods 0.000 claims 25
- 229960005486 vaccine Drugs 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 22
- 230000000813 microbial effect Effects 0.000 claims 21
- 238000009472 formulation Methods 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 14
- 238000001727 in vivo Methods 0.000 claims 10
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 10
- 108091029430 CpG site Proteins 0.000 claims 6
- -1 cationic lipid Chemical class 0.000 claims 5
- 230000003308 immunostimulating effect Effects 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 230000007503 antigenic stimulation Effects 0.000 claims 4
- 208000002672 hepatitis B Diseases 0.000 claims 4
- 230000005745 host immune response Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 229940124551 recombinant vaccine Drugs 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37934302P | 2002-05-10 | 2002-05-10 | |
| US10/290,545 US20030125292A1 (en) | 2001-11-07 | 2002-11-07 | Mucoscal vaccine and methods for using the same |
| US45429803P | 2003-03-12 | 2003-03-12 | |
| PCT/CA2003/000680 WO2003094829A2 (en) | 2002-05-10 | 2003-05-12 | Pathogen vaccines and methods for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525414A JP2005525414A (ja) | 2005-08-25 |
| JP2005525414A5 true JP2005525414A5 (https=) | 2006-06-29 |
Family
ID=29424456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004502918A Pending JP2005525414A (ja) | 2002-05-10 | 2003-05-12 | 病原体ワクチン及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1505942B1 (https=) |
| JP (1) | JP2005525414A (https=) |
| AT (1) | ATE404152T1 (https=) |
| AU (1) | AU2003229435A1 (https=) |
| CA (1) | CA2485256A1 (https=) |
| DE (1) | DE60322884D1 (https=) |
| WO (1) | WO2003094829A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2542099A1 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| JP2007531746A (ja) * | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Ｉｌ−１０応答を誘導するための免疫活性化核酸 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212085B1 (en) * | 1999-08-27 | 2007-10-31 | INEX Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
| US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| EP1441763A2 (en) * | 2001-11-07 | 2004-08-04 | Inex Pharmaceuticals Corp. | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
-
2003
- 2003-05-12 CA CA002485256A patent/CA2485256A1/en not_active Abandoned
- 2003-05-12 EP EP03722135A patent/EP1505942B1/en not_active Expired - Lifetime
- 2003-05-12 AU AU2003229435A patent/AU2003229435A1/en not_active Abandoned
- 2003-05-12 WO PCT/CA2003/000680 patent/WO2003094829A2/en not_active Ceased
- 2003-05-12 AT AT03722135T patent/ATE404152T1/de not_active IP Right Cessation
- 2003-05-12 DE DE60322884T patent/DE60322884D1/de not_active Expired - Fee Related
- 2003-05-12 JP JP2004502918A patent/JP2005525414A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103025351B (zh) | 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗 | |
| Pasquini et al. | Cytokines and costimulatory molecules as genetic adjuvants | |
| Staats et al. | Mucosal immunity to infection with implications for vaccine development | |
| Joseph et al. | Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines | |
| Sun et al. | Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination | |
| CA2289741A1 (en) | Oligonucleotide adjuvant | |
| US20040052763A1 (en) | Immunostimulatory RNA/DNA hybrid molecules | |
| US20240245767A1 (en) | Application of artificially synthesized cpg single-stranded deoxyoligonucleotide in vaccines | |
| Sun et al. | Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant | |
| JP2005532315A5 (https=) | ||
| Wang et al. | Adjuvant synergy in the response to hepatitis B vaccines | |
| CN109219449B (zh) | 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 | |
| JP2005525414A5 (https=) | ||
| Osorio et al. | Immune responses to hepatitis B surface antigen following epidermal powder immunization | |
| WO2000046365A1 (en) | Advanced antigen presentation platform | |
| US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
| Webster | Potential advantages of DNA immunization for influenza epidemic and pandemic planning | |
| EP1490100B1 (en) | Combined dna/protein vaccine compositions | |
| Liu et al. | Augmented induction of antigen-specific cytotoxic T cell responses against canine hepatitis by co-immunization with pVAX1-CpG-Loop and adjuvants in BALB/c mice | |
| WO2007028985A2 (en) | Adjuvanted vaccine | |
| EA051416B1 (ru) | Применение искусственно синтезированного одноцепочечного cpg-дезоксиолигонуклеотида в вакцинах | |
| EP4687919A1 (en) | Biological response modifiers for the treatment of subjects with underperforming immune systems and compositions thereof | |
| Portilho et al. | Different Platforms, Immune Response Modulators and Challenges in SARS-CoV-2 Vaccination | |
| Ulmer et al. | DNA vaccines: immunogenicity and preclinical efficacy | |
| Madaan | Heplisav V |